Abstract:Gene therapy for cancer aims at cell killing. Delivery of a functional tumor suppressor gene may repress tumor growth [1], but genetic alterations that result in a malignant phenotype are so complex that elimination of these clones is probably required for cure. Currently, there is already a battery of genes demonstrated to have an efficient killing effect on various tumor cells. These genes should be expressed at the right site, at the right time and at the appropriate level. Therefore, control over the delivery and expression of powerful lytic genes requires adequate regulatory mechanisms. Therapeutic targeting to malignant tissues may be extrinsic or intrinsic [2]. Extrinsic targeting implies the local effect of surgery, irradiation, or drug delivery to tumors. Intrinsic targeting involves transductional targeting (selective uptake of vector) or transcriptional targeting (selective expression of transgenes). In transductional targeting the interaction between the vector and the cell surface determines the efficiency of targeting. As a proof of principle, adenoviral surface targeting of the pancarcinomal membrane antigen results in efficient cancer gene therapy [3], rather than non-productive binding. Tumorselective transduction may also use protease-rich tumor cell surfaces [4], modification of viral envelope protein sequences, pseudotyped viruses, and antibodies as mediators for viral infection to restrict viral infection to specific cell types [5]. Transductional targeting for cancer may also successfully aim at the tumor vascular supply rather than at the tumor itself [6]. Following successful transductional targeting, expression of the foreign gene must be regulated (also referred to as transcriptional targeting or targeted gene expression). Transcription of the gene of interest will only occur under intracellular conditions in which the tissue-specific promoter is activated. Hence, regulatory signals are mandatory for controlled expression of therapeutic genes. These signals aim both at constitutive and inducible elements in the host genome, and may involve both the target tissue and adjacent tissues. The present discussion will focus on regulating promoter activity since other techniques of blocking gene transcription, such as gene disruption, do not usually affect more than 1 in 1,000 cells [7]. Gene disruption for cancer therapy is performed with targeted in-frame insertions within exons by way of homologous recombination. It aims at deleting dominant oncogenes, disrupting genes encoding for carcinogen-metabolizing enzymes [8], or at genes encoding for peptides responsible for tumor propagation [9]. Construction of viral vectors harboring cell-specific promoters has been applied for controlling gene regulation. While transcriptional regulation can generally restrict the expression of the therapeutic sequence to appropriate cells [10], promoters for genes typically expressed in a subset of malignant cells have been shown to direct therapeutic genes into the corresponding classes of tumor cells [11]. These promoters may be classified as nucleotide sequences that are already expressed by the cell, or as sequences that are not regularly expressed and may be subject to external stimuli. Regulation of therapeutic gene expression within tumor tissue may be classified into these groups: a) recognition of tissue-specific promoter sequences by distinct cellular transcription factors (trans-activators), b) exploiting oncogenes or tumor-associated peptides to construct their promoters with therapeutic genes, and c) up-regulation of protective genes in response to stress.

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

[Effect of Mitogen-Activated Protein Kinase Signal Transduction in Non-Estrogen Antagonistic Mechanism of Tamoxifen].

Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer

Studies on Resistant Induction of Breast Cancer Cell MCF-7 to Tamoxifen in Vitro

[Vascular microsutures with resorbable and nonresorbable sutures. A comparative study].

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling

Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells

Lower Beclin 1 Downregulates HER2 Expression to Enhance Tamoxifen Sensitivity and Predicts a Favorable Outcome for ER Positive Breast Cancer

EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer

Differential Gene Expression in Tamoxifen-Resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data

Global Characterization of Signalling Networks Associated with Tamoxifen Resistance in Breast Cancer

Transcriptional regulation in cancer gene therapy.

Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells

Fatty metamorphosis of the liver in malignant neoplasia. Special reference to carcinoma of the breast

Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells

Association of tamoxifen resistance and lipid reprogramming in breast cancer